Sygnature Discovery expands into early CMC development

Sygnature Discovery has announced the set-up of an Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials.

With over £1 million of capital investment already committed, the new facility and business unit will be operational in September 2021 and is being set up to work alongside the complementary chemistry, in vitro and in vivo pharmacology and DMPK capabilities.

Sygnature will create robust development strategies tailored to the characteristics of each individual API and through access to our well-equipped preformulation and formulation development laboratories rapidly and unbiasedly identify the most phase-appropriate development approach to overcome even the most complex of bioavailability challenges.

Dr Richard Weaver SVP of Pre-Clinical Development commented on the new service offering: “There is an increasing need for engaging the formulation scientist at an earlier stage and most importantly having constant and iterative dialogue with the DMPK, Pharmacology and Chemistry teams. Inadequate bioavailability in many late-stage research and development compounds is a real modern-day challenge. There is often a way forward if the reasons for the poor bioavailability are not due to DMPK reasons. A key part of this process is making the human efficacious dose prediction range as early as possible and feeding this information to the formulating scientists, along with the theoretical gains that can be made”.

Dr Mark Saunders, previously founder and CEO of Kuecept is working with Sygnature to help build this value-added capability. He said: “Already we have been able to attract leading scientific talent to drive this initiative and I am confident of the advice and experimental capability that we will be able to give to clients to help get much needed new medicines on the market with minimal hurdles and the maximal chance of the achieving right drug exposure to fit the need.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free